FLUVASTATIN - A NEW HGM-COA REDUCTASE INHIBITOR

The main causes responsible for the atherosclerosis are briefly illust rated. Subsequently, the structure, the clinical effects and the advan tages of the Fluvastatin in comparison to other HGM-CoA reductase inhi bitors are exposed. We report its efficacy in lowering the Tryglicerid es-value and the high values of Lp(a), responsible of some thrombotic effects. The drug significantly reduces the new formation of arterial plaques. It had no effects on the biliar lipids in patients with renal insufficiency and in those receiving Cyclosporine. Finally, we report on the results obtained by the FLUENT (Fluvastatin Long-term Extensio n Trial) study and on its efficacy to prevent cardiovascular diseases. Thus, Fluvastatin is a new entirely synthetic HGM-reductase inhibitor that acts on the rate-determining enzyme in cholesterol synthesis.